INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $6,860,000 | +16.7% | 117,425 | +15.9% | 0.10% | +17.2% |
| Q3 2017 | $5,880,000 | -34.2% | 101,317 | +37.3% | 0.09% | -32.0% |
| Q2 2017 | $8,936,000 | -71.8% | 73,810 | -61.7% | 0.13% | -69.2% |
| Q3 2016 | $31,685,000 | -4.9% | 192,510 | -17.6% | 0.42% | +7.5% |
| Q2 2016 | $33,326,000 | +38.7% | 233,573 | +24.9% | 0.39% | +49.0% |
| Q1 2016 | $24,029,000 | -13.9% | 187,043 | +0.1% | 0.26% | -7.5% |
| Q4 2015 | $27,909,000 | -19.8% | 186,872 | -10.9% | 0.28% | +0.7% |
| Q3 2015 | $34,800,000 | -47.7% | 209,818 | -23.9% | 0.28% | -35.0% |
| Q2 2015 | $66,543,000 | -25.3% | 275,679 | -12.7% | 0.43% | -11.6% |
| Q1 2015 | $89,076,000 | +45.0% | 315,850 | -19.8% | 0.48% | +59.2% |
| Q4 2014 | $61,441,000 | +41.6% | 393,850 | +114.9% | 0.30% | +52.0% |
| Q3 2014 | $43,385,000 | +0.0% | 183,300 | 0.0% | 0.20% | +14.9% |
| Q2 2014 | $43,374,000 | -1.1% | 183,300 | +37.8% | 0.17% | +1.2% |
| Q1 2014 | $43,862,000 | – | 133,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |